Park Min-ji's competition. The last winner is Lee Ga-young. Park Min-ji's fifth consecutive victory in a single tournament ...

"5 consecutive losses, it wasn't easy. Four consecutive losses are also a record from heaven." There was no reversal. Park ...

Going forward, Celltrion is expected to continue its current strategy, aiming to have a total of 23 biosimilar products by 2030, covering therapeutic areas such as immunology and oncology. We sell ...

In the last month, the FDA has granted interchangeability status to additional adalimumab biosimilars.  Biosimilars with an ...

Since the European Medicines Agency (EMA) approval of omalizumab in 2005 as the first ever biologic for severe asthma, the ...

South Korean biopharmaceutical firm Celltrion announced Wednesday that the market share of Remsima SC, the subcutaneous ...

Developed by South Korean firm Celltrion (Kosdaq: 068270), with this approval, Yuflyma is now fully interchangeable with the ...

SEOUL—South Korea pledged on Wednesday more support measures for key export industries such as biopharmaceuticals and autos, as US President Donald Trump’s sweeping tariffs weigh on the ...

Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted an expanded interchangeable ...

INCHEON, South Korea, May 21, 2025 /PRNewswire/ -- Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted an expanded interchangeable designation for YUFLYMA ...

Data suggest potential for superior tumor selectivity, potent efficacy, and improved safety profile Abpro and Celltrion have a strategic partnership for worldwide development and commercialization of ...

Abpro Holdings, Inc. and Celltrion have announced a strategic partnership for the global development of ABP-102/CT-P72, a bispecific T-cell engager designed to target HER2-positive cancers ...